Fosun Pharmaceutical announced that recently, its holding subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd.'s application for dobutamine hydrochloride injection drug registration was approved by the State Drug Administration. The approved indications are heart failure due to decreased myocardial contractility during organic heart disease. As of June 2026, the Group has invested a total of about 5.09 million yuan in research and development of this drug. In 2025, the sales volume of the drug in China was about 79 million yuan. The approved listing will expand the Group's related product specifications, but the sales situation is uncertain.

Fosun Pharmaceutical announced that recently, its holding subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd.'s application for dobutamine hydrochloride injection drug registration was approved by the State Drug Administration. The approved indications are heart failure due to decreased myocardial contractility during organic heart disease. As of June 2026, the Group has invested a total of about 5.09 million yuan in research and development of this drug. In 2025, the sales volume of the drug in China was about 79 million yuan. The approved listing will expand the Group's related product specifications, but the sales situation is uncertain.